Kither Biotech has begun dosing patients with KIT2014, its experimental treatment for chronic obstructive pulmonary disease, in a Phase 1b/2a clinical study, according to The Manila Times.
The company announced the start of patient dosing on Tuesday, September 29, 2026, the outlet reported. The trial is designed to cover both an early safety phase and a later phase that typically looks at how well a drug works, though The Manila Times did not disclose how many patients are enrolled, where the study sites are located, or what endpoints researchers will measure.
COPD is a long-term lung condition that makes breathing difficult and is commonly linked to smoking and other irritants. The Phase 1b portion of a study generally focuses on confirming dosing and checking for side effects, while a Phase 2a stage usually gathers early signals about whether a treatment helps patients. Combining the two phases can allow a company to move faster between questions of safety and early effectiveness.
Kither Biotech has not released additional details about KIT2014 beyond the start of dosing, and no results from the study have been made public, according to the report.
What to watch next: whether Kither Biotech discloses enrollment targets, trial locations, or early data from the Phase 1b/2a study, and how the COPD treatment landscape responds as more information becomes available.
